Skip to content Skip to footer

Precise genome-editing technology to cure HIV infections

PROVIREX employs site-specific recombinase-based genome cutting technology to precisely excise chromosomally integrated viral genomes (proviruses). The major advantage of site-specific recombinases is that they function independently of host DNA repair. Therefore, in contrast to other gene editing technologies, they act with nucleotide precision producing completely error-free recombinants.

The engineered recombinase Brec1 excises HIV-1 proviruses with high specificity from the genome of infected host cells. Brec1 activity has unparalleled and lasting antiviral effects in vitro and in vivo. Consequently, plasma viral load declines to levels below the detection limits of the most sensitive assay systems. No viral rebound has been observed.

New HIV therapy with the chance of a cure

Our vision to improve the lives of people with HIV.

Introduction video for the Innovation Award 2023 on behalf of WRG Wirtschaftsförderung Region Göttingen GmbH.